title: JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
abstract: OBJECTIVE
  To identify non-quinazoline kinase inhibitors effective against drug resistant mutants of epidermal growth factor receptor (EGFR).
  
  
  METHODS
  A kinase inhibitor library was subjected to screening for specific inhibition pertaining to the in vitro kinase activation of EGFR with the gatekeeper mutation T790M, which is resistant to small molecular weight tyrosine kinase inhibitors (TKIs) for EGFR in non-small cell lung cancers (NSCLCs). This inhibitory effect was confirmed by measuring autophosphorylation of EGFR T790M/L858R in NCI-H1975 cells, an NSCLC cell line harboring the gatekeeper mutation. The effects of a candidate compound, Janus kinase 3 (JAK3) inhibitor VI, on cell proliferation were evaluated using the MTT assay and were compared between T790M-positive and -negative lung cancer cell lines. JAK3 inhibitor VI was modeled into the ATP-binding pocket of EGFR T790M/L858R. Potential physical interactions between the compound and kinase domains of wild-type (WT) or mutant EGFRs or JAK3 were estimated by calculating binding energy. The gatekeeper residues of EGFRs and JAKs were aligned to discuss the similarities among EGFR T790M and JAKs.
  
  
  RESULTS
  We found that JAK3 inhibitor VI, a known inhibitor for JAK3 tyrosine kinase, selectively inhibits EGFR T790M/L858R, but has weaker inhibitory effects on the WT EGFR in vitro. JAK3 inhibitor VI also specifically reduced autophosphorylation of EGFR T790M/L858R in NCI-H1975 cells upon EGF stimulation, but did not show the inhibitory effect on WT EGFR in A431 cells. Furthermore, JAK3 inhibitor VI suppressed the proliferation of NCI-H1975 cells, but showed limited inhibitory effects on the WT EGFR-expressing cell lines A431 and A549. A docking simulation between JAK3 inhibitor VI and the ATP-binding pocket of EGFR T790M/L858R predicted a potential binding status with hydrogen bonds. Estimated binding energy of JAK3 inhibitor VI to EGFR T790M/L858R was more stable than its binding energy to the WT EGFR. Amino acid sequence alignments revealed that the gatekeeper residues of JAK family kinases are methionine in WT, similar to EGFR T790M, suggesting that TKIs for JAKs may also be effective for EGFR T790M.
  
  
  CONCLUSIONS
  Our findings demonstrate that JAK3 inhibitor VI is a gatekeeper mutant selective TKI and offer a strategy to search for new EGFR T790M inhibitors.
authors.affiliation: Naoyuki Nishiya, Yusuke Oku, Yoshimasa Uehara, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Nishiya
authors.affiliation: Naoyuki Nishiya, Yusuke Oku, Yoshimasa Uehara, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan.
authors.forename: Yasumitsu
authors.initials: Y
authors.lastname: Sakamoto
authors.affiliation: Naoyuki Nishiya, Yusuke Oku, Yoshimasa Uehara, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oku
authors.affiliation: Naoyuki Nishiya, Yusuke Oku, Yoshimasa Uehara, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan.
authors.forename: Takamasa
authors.initials: T
authors.lastname: Nonaka
authors.affiliation: Naoyuki Nishiya, Yusuke Oku, Yoshimasa Uehara, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, Yahaba, Iwate 028-3694, Japan.
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Uehara
keywords: Epidermal growth factor receptor; Gatekeeper mutation; Non-small cell lung cancers; Tyrosine kinase inhibitor